Posts by AiViva BioPharma
AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer Cosa Mesa, Calif. December 9, 2024 (GLOBE NEWSWIRE) – AiViva Biopharma Inc.,…
Read MoreAiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema • Novel JEL™ Technology for Periocular Administration Costa Mesa, Calif.,…
Read MoreAiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
Cosa Mesa, Calif., December 11, 2023 (GlobeNewswire) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial administering AIV001 (axitinib) to patients diagnosed with basal cell…
Read MoreAiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors
Costa Mesa, Calif., September 18, 2023 (GLOBENEWSWIRE) – AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Dr.…
Read MoreAiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
Costa Mesa, Calif., August 30, 2023 (GlobeNewswire) – AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Mr.…
Read MoreAiViva BioPharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
Costa Mesa, Calif., May 22, 2023 – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of…
Read MoreAiViva BioPharma Announces New Patent Received
Newport Beach, California – August 15, 2022 – AiViva Biopharma, a clinical-stage biopharmaceutical company has received patent US 11,400,089 on August 2, 2022. This patent is a method of use…
Read MoreAiViva BioPharma is recognized by Life Sciences Review as Top 20 Clinical-Stage Biopharmaceutical Company for 2022
Life Sciences Review Recognizes AiViva Top 20 Clinical-Stage Biopharmaceutical Companies of 2022Downdload PDF File > Life Sciences Review Recognizes AiViva Page 2Download PDF File >
Read MoreAiViva BioPharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
NEWPORT BEACH, Calif., October 2, 2020 (GLOBE NEWSWIRE) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun dosing patients diagnosed with superficial or nodular basal cell…
Read MoreAiViva BioPharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing NEWPORT BEACH, Calif., June 25, 2020 (GLOBE NEWSWIRE) — AiViva Biopharma Inc.,…
Read More